Galcanezumab (Norwegian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Galcanezumab" in Norwegian language version.

refsWebsite

Global rank Norwegian rank

3fda.gov

447^th place

2,058^th place

2web.archive.org

1^st place

1ama-assn.org

3,257^th place

3,082^nd place

1who.int

195^th place

381^st place

1europa.eu

68^th place

84^th place

1cnbc.com

220^th place

689^th place

1reuters.com

49^th place

132^nd place

ama-assn.org (Global: 3,257^th place; Norwegian: 3,082^nd place)

"Statement on a Nonproprietary Name Adopted by the USAN Council - Galcanezumab", American Medical Association.

cnbc.com (Global: 220^th place; Norwegian: 689^th place)

«US FDA approves Lilly migraine drug at a price that is the same as its rivals». CNBC. CNBC. Reuters. 28. september 2018. Besøkt 29. september 2018.

europa.eu (Global: 68^th place; Norwegian: 84^th place)

ema.europa.eu

«Emgality EPAR». Besøkt 28.04.2020.

fda.gov (Global: 447^th place; Norwegian: 2,058^th place)

fda.gov

(pressemelding) https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-episodic-cluster-headache-reduces-frequency-attacks. Manglende eller tom |tittel= (hjelp)
«Drug Trials Snapshots: Emgality». U.S. Food and Drug Administration (FDA). Arkivert fra originalen 7. desember 2019. Besøkt 7. desember 2019.

accessdata.fda.gov

«Drug Approval Package: Emgality (galcanezumab-gnlm)». U.S. Food and Drug Administration (FDA). Arkivert fra originalen 7. desember 2019. Besøkt 7. desember 2019.

reuters.com (Global: 49^th place; Norwegian: 132^nd place)

Erman, Michael. «FDA approves Lilly's migraine drug as first ever cluster headache treatment». Reuters. Besøkt 28. april 2020.

web.archive.org (Global: 1^st place; Norwegian: 1^st place)

«Drug Approval Package: Emgality (galcanezumab-gnlm)». U.S. Food and Drug Administration (FDA). Arkivert fra originalen 7. desember 2019. Besøkt 7. desember 2019.
«Drug Trials Snapshots: Emgality». U.S. Food and Drug Administration (FDA). Arkivert fra originalen 7. desember 2019. Besøkt 7. desember 2019.

who.int (Global: 195^th place; Norwegian: 381^st place)

«International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114» (PDF). WHO Drug Information. 29 (4). 2015 – via World Health Organization.

Galcanezumab (Norwegian Wikipedia)

ama-assn.org (Global: 3,257th place; Norwegian: 3,082nd place)

cnbc.com (Global: 220th place; Norwegian: 689th place)

europa.eu (Global: 68th place; Norwegian: 84th place)